Terms: = Breast cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Treatment
272 results:
1. Peptide Inhibitor Targeting the Extraterminal Domain in brd4 Potently Suppresses breast cancer Both
Huang QX; Fan DM; Zheng ZZ; Ran T; Bai A; Xiao RQ; Hu GS; Liu W
J Med Chem; 2024 Apr; 67(8):6658-6672. PubMed ID: 38569135
[TBL] [Abstract] [Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 2-Low breast cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of Cold Atmospheric Plasma vs. Chemotherapy in Triple-Negative breast cancer: A Systematic Review.
Almeida-Ferreira C; Marto CM; Carmo C; Almeida-Ferreira J; Frutuoso C; Carvalho MJ; Botelho MF; Laranjo M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542225
[TBL] [Abstract] [Full Text] [Related]
4. Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative breast cancer Therapy.
Bai L; Liu H; You R; Jiang X; Zhang T; Li Y; Shan T; Qian Z; Wang Y; Liu Y; Li C
Mol Pharm; 2024 May; 21(5):2148-2162. PubMed ID: 38536949
[TBL] [Abstract] [Full Text] [Related]
5. Degree of satisfaction of women treated with reconstruction and dermopigmentation of the nipple-areola complex after breast reconstruction.
Padullés-Escarré A; López-Ojeda A; Sánchez-Egea A; Adamuz-Tomás J
Enferm Clin (Engl Ed); 2024; 34(2):82-89. PubMed ID: 38484934
[TBL] [Abstract] [Full Text] [Related]
6. A PROTAC Augmenter for Photo-Driven Pyroptosis in breast cancer.
Huang D; Zou Y; Huang H; Yin J; Long S; Sun W; Du J; Fan J; Chen X; Peng X
Adv Mater; 2024 May; 36(21):e2313460. PubMed ID: 38364230
[TBL] [Abstract] [Full Text] [Related]
7. Comparative assessment of direct and indirect cold atmospheric plasma effects, based on helium and argon, on human glioblastoma: an in vitro and in vivo study.
Bakhtiyari-Ramezani M; Nohekhan M; Akbari ME; Abbasvandi F; Bayat M; Akbari A; Nasiri M
Sci Rep; 2024 Feb; 14(1):3578. PubMed ID: 38347045
[TBL] [Abstract] [Full Text] [Related]
8. Diagnostic Accuracy of Immunohistochemistry for HER2-Positive breast cancer.
Thanasan S; Sukhakul K; Chitpakdee S; Kitkumthorn N
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4321-4327. PubMed ID: 38156869
[TBL] [Abstract] [Full Text] [Related]
9. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
Ho IW; Pan YL; Lai JI; Liu CY
Thorac Cancer; 2024 Feb; 15(4):339-346. PubMed ID: 38149471
[TBL] [Abstract] [Full Text] [Related]
10. Design and synthesis of dual brd4/Src inhibitors for treatment of triple-negative breast cancer.
Wang Y; Huang A; Chen L; Sun F; Zhao M; Zhang M; Xie Y; Xu S; Li M; Hong L; Li G; Wang R
Eur J Med Chem; 2024 Jan; 264():116009. PubMed ID: 38070430
[TBL] [Abstract] [Full Text] [Related]
11. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in breast cancer.
He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
[TBL] [Abstract] [Full Text] [Related]
12. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.
Wang P; Zhou R; Zhou R; Feng S; Zhao L; Li W; Lin J; Rajapakse A; Lee CH; Furnari FB; Burgess AW; Gunter JH; Liu G; Ostrikov KK; Richard DJ; Simpson F; Dai X; Thompson EW
Redox Biol; 2024 Feb; 69():102976. PubMed ID: 38052106
[TBL] [Abstract] [Full Text] [Related]
13. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
14. Interactions between brd4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.
Pascual-Reguant L; Serra-Camprubí Q; Datta D; Cianferoni D; Kourtis S; Gañez-Zapater A; Cannatá C; Espinar L; Querol J; García-López L; Musa-Afaneh S; Guirola M; Gkanogiannis A; Miró Canturri A; Guzman M; Rodríguez O; Herencia-Ropero A; Arribas J; Serra V; Serrano L; Tian TV; Peiró S; Sdelci S
EMBO Mol Med; 2023 Dec; 15(12):e18459. PubMed ID: 37937685
[TBL] [Abstract] [Full Text] [Related]
15. brd4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
Kim SL; Choi HS; Lee DS
Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
[TBL] [Abstract] [Full Text] [Related]
16. Tumor Microenvironment Modulating CaCO
Dong Z; Liu Y; Wang C; Hao Y; Fan Q; Yang Z; Li Q; Feng L; Liu Z
Adv Mater; 2024 Mar; 36(9):e2308254. PubMed ID: 37918820
[TBL] [Abstract] [Full Text] [Related]
17. The Usefulness of Elastin Staining to Detect Vascular Invasion in cancer.
Gonzalez J; Bahmad HF; Ocejo S; Abreu A; Popp M; Gogola S; Fernandez V; Recine M; Poppiti R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894944
[TBL] [Abstract] [Full Text] [Related]
18. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Schmidt M; Nitz U; Reimer T; Schmatloch S; Graf H; Just M; Stickeler E; Untch M; Runnebaum I; Belau A; Huober J; Jackisch C; Hofmann M; Krocker J; Nekljudova V; Loibl S;
Eur J Cancer; 2023 Nov; 194():113324. PubMed ID: 37797387
[TBL] [Abstract] [Full Text] [Related]
19. Discovery of Novel Fedratinib-Based HDAC/JAK/brd4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative breast cancer.
Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
[TBL] [Abstract] [Full Text] [Related]
20. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
[TBL] [Abstract] [Full Text] [Related]
[Next]
